These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15217218)

  • 1. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas.
    Grünhagen DJ; Brunstein F; ten Hagen TL; van Geel AN; de Wilt JH; Eggermont AM
    Cancer Treat Res; 2004; 120():65-79. PubMed ID: 15217218
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
    Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
    Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
    Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Isolated extremity perfusion with TNF-alpha and melphalan in unresectable soft tissue sarcoma. Indications, principles and technique].
    Taeger G; Ruchholtz S; Niebel W; Müller S; Nast-Kolb D
    Unfallchirurg; 2004 Jul; 107(7):619-23. PubMed ID: 15252711
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
    Jakob J; Hohenberger P
    Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities.
    Grünhagen DJ; de Wilt JH; van Geel AN; Verhoef C; Eggermont AM
    Recent Results Cancer Res; 2009; 179():257-70. PubMed ID: 19230545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
    Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
    Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
    Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
    Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current uses of isolated limb perfusion in the clinic and a model system for new strategies.
    Eggermont AM; de Wilt JH; ten Hagen TL
    Lancet Oncol; 2003 Jul; 4(7):429-37. PubMed ID: 12850194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.
    Eggermont AM; ten Hagen TL
    Curr Oncol Rep; 2001 Jul; 3(4):359-67. PubMed ID: 11389822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome.
    Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
    J Surg Oncol; 2011 Jun; 103(7):648-55. PubMed ID: 21337343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
    Hohenberger P; Bida B; Schlag PM
    Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
    [No Abstract]   [Full Text] [Related]  

  • 18. Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.
    Verhoef C; de Wilt JH; Grünhagen DJ; van Geel AN; ten Hagen TL; Eggermont AM
    Curr Treat Options Oncol; 2007 Dec; 8(6):417-27. PubMed ID: 18066703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.